[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Matrix Medical Network\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":151},{"warningLetters":4,"total":150},[5,31,54,75,93,112,128],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},952,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-04-22T04:00:00Z\">04\u002F22\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-09T04:00:00Z\">04\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnoah-medical-corporation-702414-04092025\">Noah Medical Corporation\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FManufacture\u002FPacking\u002FStorage\u002FInstallation\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jian Zhang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Noah Medical Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2075 Zanker Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Jose\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>95131\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jianzhang@noahmed.com\"> jianzhang@noahmed.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #702414\u003C\u002Fp>\u003Cp>April 09, 2025\u003Cbr>\u003Cbr>Dear Ms. Zhang:\u003C\u002Fp>\u003Cp>During an inspection of your firm located at 2075 Zanker Road, San Jose, CA 95131 on October 28, 2024, through November 26, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures bronchoscopes and accessories (branded as the Galaxy System). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Richard W. Reeves, Vice President Quality Assurance and Regulatory Affairs, dated December 18, 2024, and January 21, 2025, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>Specifically, your firm failed to adequately establish your “Corrective and Preventive Action (CAPA)” procedure (SOP-019 Rev. B, Effective Date: 10\u002F30\u002F2024), as your firm did not adequately conduct and document CAPA investigations. For example, according to your procedure, a Corrective Action\u002FPreventive Action (CAPA) process shall be established to ensure “investigations are conducted to a degree sufficient to determine the root cause.” However, 2 out of 17 CAPA records selected for review by our investigators did not identify the root causes and necessary corrective and preventive actions as required by your CAPA procedure. The following describes the two CAPA records:\u003C\u002Fp>\u003Cp>a. CAPA 24-007 dated 9\u002F11\u002F2024: Your firm failed to conduct adequate investigations as required by your CAPA procedure. For example, your firm failed to explore sufficiently to determine the root cause for “biopsy tools couldn’t pass through bronchoscope’s working channels.” You did not investigate, sufficiently to determine the root cause, the lot-to-lot variation of the distal end measurements of the working channels and how it may impact your root cause analysis.\u003C\u002Fp>\u003Cp>b. CAPA 23-005 dated 4\u002F14\u002F2023: This CAPA record reported two scope pouches leaking due to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> poking holes in the pouches during shelf-life\u002Fpackaging transportation study Protocol “Design Verification Protocol for Bronchoscope Packaging,” (DOC: TP-099 Rev. B), and test report #WP-12154A. During execution of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging testing of the sterile bronchoscope, a test failure was noted during a gross leak testing of the scope pouches. Your firm did not evaluate how many scope pouches were leaking to identify other potential causes of the failed leak test, such as quality issues with your suppliers. Subsequently, your scope pouches failed leak test during a \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study (test report number #WP-16128A), but your firm did not document the cause of the leak nor reference this failed leak test in CAPA 23-005.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-028. You indicate that your firm made immediate corrections to CAPA 24-007; plans to contract with a third-party to retrospectively review all open and closed CAPAs, including the CAPAs cited during the last inspection; revised the CAPA process; and completed relevant training on the revised CAPA procedure including revised work instructions. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA 24-028 record.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>Specifically, your complaint procedure, “Complaint Management,” (SOP-025, Rev. G, Effective Date: 10\u002F28\u002F2024) has not been adequately established as your firm did not adequately conduct and\u002For document complaint investigations. For example,\u003C\u002Fp>\u003Cp>a. Your procedure indicates complaint investigations are conducted to “determine the cause of any product defects and\u002For malfunctions, whether product met specifications, or whether product specifications were met, but were inadequate.” Your firm did not follow your procedure as exemplified below:\u003C\u002Fp>\u003Cp>i. Complaint #00003531 described a failure to acquire live video feed upon attaching the scope to the instrument driving mechanism (IDM). Your firm did not adequately investigate the cause(s) of camera image loss.\u003C\u002Fp>\u003Cp>ii. Complaint #00002229 involved a user experiencing scope buckling errors due to severe kink in the distal area and the user had to replace with another scope. However, your firm did not investigate cause(s) for the kinks.\u003C\u002Fp>\u003Cp>iii. Complaint #00003614 described a patient experiencing excessive bleeding during Galaxy-assisted procedure. Complaint record states “scope buckling malfunction was observed.” However, your firm did not identify cause(s) for scope buckling.\u003C\u002Fp>\u003Cp>b. Your procedure states complaint “investigation examples may include, but is not limited to … batch record review to determine if there were nonconformances, material used, or process steps that could have contributed to the complaint.” For complaint #00003610 involving a patient who had pneumothorax while undergoing a Galaxy-assisted biopsy procedure for a 14mm lesion in the left upper lobe, the patient got a chest tube insert and was admitted to the hospital for 3 days. Your firm did not review batch records and other quality data sources for the bronchoscope used in this procedure to investigate and determine whether your device could have contributed to the patient’s injury.\u003C\u002Fp>\u003Cp>c. Your procedure states that “additional information from the complainant may be required to process a complaint” and that “various methods of communication … should be attempted in order to make a good faith effort to contact the complainant.” However, your firm failed to conduct and\u002For document a good faith effort to obtain additional information to support the complaint investigations. For example:\u003C\u002Fp>\u003Cp>i. Complaint #00003544 has a death reported due to excess bleeding when a patient was undergoing a Galaxy-assisted bronchoscopy procedure. According to your firm’s representative and associated complaint record, the physician stated that “the patient had possibly forgotten to stop taking blood thinners” and patient possibly was “puncture[d] by biopsy forceps.” Your firm’s Clinical Engineer reviewed the video of the procedure and said she could not see the forceps puncturing the blood vessel because there was too much blood blocking the camera view. Your firm did not make any attempt(s) to verify the causes further.\u003C\u002Fp>\u003Cp>ii. Complaint #00003337 involves a procedure that was aborted due to broken joysticks on two different controllers resulting in the scope drifting significantly into the patient’s right upper lobe of the lung. There was no documented information on when the patient was rescheduled for another procedure nor if the patient experienced any adverse event(s) after aborted procedures.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-025, CAPA 24-026, and CAPA 24-015. Your responses indicate that your firm has made some progress including completion of the root cause investigation for CAPA 24-015. However, the CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for design control, as required by 21 CFR 820.30.\u003C\u002Fp>\u003Cp>Specifically, your design control procedure, “Design Controls” (SOP-002, Rev. G, Effective Date: 10\u002F21\u002F2024), has not been adequately established.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> For example, your design control procedure states that “Design verification and validation shall be conducted in accordance with SOP-033…to ensure design outputs meet the design input requirements and the product meets its intended use.” However, your firm failed to establish the procedure as follows:\u003C\u002Fp>\u003Cp>a. Your firm failed to adequately conduct design validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> biopsy tools, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, listed on page 23 of IFU Rev J, Effective Date: 09\u002F25\u002F2024. During design validation, your firm only performed design validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and used the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as the worst-case tool for biopsy tool passage. Furthermore, your firm only tested biopsy tool passage in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> configuration of the bronchoscope instead of \u003Cstrong>(b)(4)\u003C\u002Fstrong> configuration to account for bending of the bronchoscope. Your firm initiated CAPA 24-007 after the complaint trend associated with biopsy tools not passing through working channel “exceeded the required action threshold.”\u003C\u002Fp>\u003Cp>b. Your procedure failed to define the requirements to test sterility as part of the shelf-life validations. Your bronchoscopes are sold as sterile with an expiration date of two years, but your firm did not test product sterility as part of the shelf-life validations in the following protocols:\u003C\u002Fp>\u003Cp>i. Protocol #TP-008, Revision E, describing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study, titled: “Galaxy Bronchoscope Verification Test Plan” and Summary Report #TR-087, Revision C.\u003C\u002Fp>\u003Cp>ii. Protocol #TP-008, Revision E, describing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study, titled: “Galaxy Bronchoscope Verification Test Plan,” and Summary Report WP-16128A, Date Reviewed 05\u002F08\u002F2024.\u003C\u002Fp>\u003Cp>iii. Protocol #TP-099, Revision B, relating to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study, titled: “Design Verification Protocol for Bronchoscope Packaging (includes \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> configurations)” and Summary Report #TR-378, Revision A.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-016 and CAPA 24-018. You indicate “as part of the Corrective Action, all instances of Design Verification and Validation of Requirements are being reviewed and where assumptions were made, these are being tested against documented evidence” (your firm’s response dated January 21, 2025). The CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\u003C\u002Fp>\u003Cp>4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\u003C\u002Fp>\u003Cp>Specifically, your procedure, “Nonconforming Material,” (SOP-018 Rev. G, Effective Date: 09\u002F24\u002F2024,), has not been adequately implemented. Your firm failed to conduct investigations to identify the root cause(s) as required by your nonconforming material procedure. For example:\u003C\u002Fp>\u003Cp>a. NCR 0367 (Dated 04\u002F11\u002F2024) involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> bronchoscopes failing leak test due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the working channels (part \u003Cstrong>(b)(4)\u003C\u002Fstrong>). However, your firm did not conduct investigation to identify the root cause(s) of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> nor implement a SCAR with your supplier.\u003C\u002Fp>\u003Cp>b. NCR 0605 (Dated 09\u002F20\u002F2024) involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> bronchoscopes failing leak tests. One failure was due to the working channel not adequately bonded to the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the other \u003Cstrong>(b)(4)\u003C\u002Fstrong> failures were due to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm did not conduct investigation to identify the root cause(s) for the inadequate bonding nor the exposed \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>c. NCR 0071 (Dated 07\u002F27\u002F2023) involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> working channels found to have kinks. However, your firm failed to investigate to identify the root cause(s) for the kinks nor implement a SCAR with your supplier.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-021. Your responses indicate that your firm plans to update your procedures, conduct training once the revised procedures are complete, and address immediate issues including review of all NCRs to date (starting from May 2023, approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> NCRs) and identify those which require investigation or revisions. Also, you indicate that there was immediate containment for the NCRs cited during the recent inspection and your firm issued SCAR number 24-010 to your supplier to determine the root cause of working channel defects. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\u003C\u002Fp>\u003Cp>5. Failure to establish and maintain procedures for rework, to include retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications, as required by 21 CFR 820.90(b)(2). Rework and reevaluation activities, including a determination of any adverse effect from the rework upon the product, shall be documented in the device history record (DHR), as required by 21 CFR 820.90(b)(2).\u003C\u002Fp>\u003Cp>Specifically, your procedure, “Rework and Deviation,” (SOP-020 Rev. B, Effective Date: 11\u002F28\u002F2022), has not been adequately established. For example, your Rework and Deviation procedure failed to include the requirement for determining whether there has been any adverse effect from rework upon the product when documenting rework and reevaluation activities. For example, the DHR for “Galaxy, Cart, \u003Cstrong>(b)(4)\u003C\u002Fstrong>” CRB-1516 (part number \u003Cstrong>(b)(4)\u003C\u002Fstrong>), relates to nonconformance #108, which described a nonconformance with an instrument driving mechanism (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) on the Galaxy System robot. This nonconformance resulted in frozen bronchoscope camera images. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> were replaced. However, your firm did not document a determination of whether there has been any adverse effect from reworking the \u003Cstrong>(b)(4)\u003C\u002Fstrong> upon the “Galaxy, Cart, \u003Cstrong>(b)(4)\u003C\u002Fstrong>” CRB-1516.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-022. Your responses indicate that you have revised your Rework and Deviation procedure and plan to conduct “a retrospective review of NCRs, rework, complaints and field repairs for all shipped systems to date as well as those in inventory to determine if any adverse effects are evident, and plan to implement corrections” (your response dated January 21, 2025). However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Galaxy Systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the devices that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fp>\u003Cp>For example, the information included for Complaint #00003935 and #00003614 reasonably suggests that during a procedure where your firm’s Galaxy System was used, the patients sustained injuries resulting in bleeding that were treated with irrigation and suction (Complaint #00003935) and Levophed administration (Complaint #00003614). We determined that these interventions were necessitated to prevent permanent impairment of a body function or permanent damage to a body structure (21 CFR 803.3(w)(3)). Your firm became aware of Complaint #00003935 on August 21, 2024, and FDA has not yet received an MDR for the corresponding MDR reportable event.\u003C\u002Fp>\u003Cp>Your firm became aware of Complaint #00003614 on July 24, 2024. Although the corresponding MDR #3021325287-2024-00024 was received by FDA on January 13, 2025, it was received beyond the 30-calendar-day timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. The responses indicate that your firm initiated a root cause investigation, plans to streamline its MDR reporting process, and is conducting a retrospective review of complaints for reportability. However, in the responses, your firm did not include documentation or evidence to demonstrate that the systemic corrective actions have been fully implemented, as these efforts are still ongoing.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, the document titled “Medical Device Reporting,” Doc# SOP-026, Rev. C, dated 10\u002F28\u002F2024, was presented as your firm’s written MDR procedure. After reviewing the MDR procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits the definitions of the terms “caused or contributed” from 21 CFR 803.3 and “reasonably suggests” found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>Your firm’s responses did not address the noted procedural deficiencies, as these were not included in the FDA Form 483.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: cdrhenforcement@fda.hhs.gov. Please include in the subject line, CMS case #702414 when replying. If you have any questions about the contents of this letter, please contact: Linda Linh Adams, Compliance Officer, at lindalinh.adams@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>Cc: Sam Mostafavi, Regulatory Advisor\u002F Management Representative, at sammostafavi@noahmed.com\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA also received a response dated February 18, 2025. This letter does not address that response given timing considerations. That response will be considered along with any response to this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under 21 CFR 820.3(k), “establish” means define, document (in writing or electronically), and implement.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJian Zhang\n\nRecipient Title\n\nChief Executive Officer\n\nNoah Medical Corporation\n\n2075 Zanker Road\n\nSan Jose, CA 95131\n\nUnited States\n\njianzhang@noahmed.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #702414\nApril 09, 2025\n\nDear Ms. Zhang:\nDuring an inspection of your firm located at 2075 Zanker Road, San Jose, CA 95131 on October 28, 2024, through November 26, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures bronchoscopes and accessories (branded as the Galaxy System). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Richard W. Reeves, Vice President Quality Assurance and Regulatory Affairs, dated December 18, 2024, and January 21, 2025, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm1. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, your firm failed to adequately establish your “Corrective and Preventive Action (CAPA)” procedure (SOP-019 Rev. B, Effective Date: 10\u002F30\u002F2024), as your firm did not adequately conduct and document CAPA investigations. For example, according to your procedure, a Corrective Action\u002FPreventive Action (CAPA) process shall be established to ensure “investigations are conducted to a degree sufficient to determine the root cause.” However, 2 out of 17 CAPA records selected for review by our investigators did not identify the root causes and necessary corrective and preventive actions as required by your CAPA procedure. The following describes the two CAPA records:\na. CAPA 24-007 dated 9\u002F11\u002F2024: Your firm failed to conduct adequate investigations as required by your CAPA procedure. For example, your firm failed to explore sufficiently to determine the root cause for “biopsy tools couldn’t pass through bronchoscope’s working channels.” You did not investigate, sufficiently to determine the root cause, the lot-to-lot variation of the distal end measurements of the working channels and how it may impact your root cause analysis.\nb. CAPA 23-005 dated 4\u002F14\u002F2023: This CAPA record reported two scope pouches leaking due to the (b)(4) poking holes in the pouches during shelf-life\u002Fpackaging transportation study Protocol “Design Verification Protocol for Bronchoscope Packaging,” (DOC: TP-099 Rev. B), and test report #WP-12154A. During execution of the (b)(4) aging testing of the sterile bronchoscope, a test failure was noted during a gross leak testing of the scope pouches. Your firm did not evaluate how many scope pouches were leaking to identify other potential causes of the failed leak test, such as quality issues with your suppliers. Subsequently, your scope pouches failed leak test during a (b)(4) aging study (test report number #WP-16128A), but your firm did not document the cause of the leak nor reference this failed leak test in CAPA 23-005.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-028. You indicate that your firm made immediate corrections to CAPA 24-007; plans to contract with a third-party to retrospectively review all open and closed CAPAs, including the CAPAs cited during the last inspection; revised the CAPA process; and completed relevant training on the revised CAPA procedure including revised work instructions. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA 24-028 record.\n2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\nSpecifically, your complaint procedure, “Complaint Management,” (SOP-025, Rev. G, Effective Date: 10\u002F28\u002F2024) has not been adequately established as your firm did not adequately conduct and\u002For document complaint investigations. For example,\na. Your procedure indicates complaint investigations are conducted to “determine the cause of any product defects and\u002For malfunctions, whether product met specifications, or whether product specifications were met, but were inadequate.” Your firm did not follow your procedure as exemplified below:\ni. Complaint #00003531 described a failure to acquire live video feed upon attaching the scope to the instrument driving mechanism (IDM). Your firm did not adequately investigate the cause(s) of camera image loss.\nii. Complaint #00002229 involved a user experiencing scope buckling errors due to severe kink in the distal area and the user had to replace with another scope. However, your firm did not investigate cause(s) for the kinks.\niii. Complaint #00003614 described a patient experiencing excessive bleeding during Galaxy-assisted procedure. Complaint record states “scope buckling malfunction was observed.” However, your firm did not identify cause(s) for scope buckling.\nb. Your procedure states complaint “investigation examples may include, but is not limited to … batch record review to determine if there were nonconformances, material used, or process steps that could have contributed to the complaint.” For complaint #00003610 involving a patient who had pneumothorax while undergoing a Galaxy-assisted biopsy procedure for a 14mm lesion in the left upper lobe, the patient got a chest tube insert and was admitted to the hospital for 3 days. Your firm did not review batch records and other quality data sources for the bronchoscope used in this procedure to investigate and determine whether your device could have contributed to the patient’s injury.\nc. Your procedure states that “additional information from the complainant may be required to process a complaint” and that “various methods of communication … should be attempted in order to make a good faith effort to contact the complainant.” However, your firm failed to conduct and\u002For document a good faith effort to obtain additional information to support the complaint investigations. For example:\ni. Complaint #00003544 has a death reported due to excess bleeding when a patient was undergoing a Galaxy-assisted bronchoscopy procedure. According to your firm’s representative and associated complaint record, the physician stated that “the patient had possibly forgotten to stop taking blood thinners” and patient possibly was “puncture[d] by biopsy forceps.” Your firm’s Clinical Engineer reviewed the video of the procedure and said she could not see the forceps puncturing the blood vessel because there was too much blood blocking the camera view. Your firm did not make any attempt(s) to verify the causes further.\nii. Complaint #00003337 involves a procedure that was aborted due to broken joysticks on two different controllers resulting in the scope drifting significantly into the patient’s right upper lobe of the lung. There was no documented information on when the patient was rescheduled for another procedure nor if the patient experienced any adverse event(s) after aborted procedures.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-025, CAPA 24-026, and CAPA 24-015. Your responses indicate that your firm has made some progress including completion of the root cause investigation for CAPA 24-015. However, the CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\n3. Failure to establish and maintain procedures for design control, as required by 21 CFR 820.30.\nSpecifically, your design control procedure, “Design Controls” (SOP-002, Rev. G, Effective Date: 10\u002F21\u002F2024), has not been adequately established.2 For example, your design control procedure states that “Design verification and validation shall be conducted in accordance with SOP-033…to ensure design outputs meet the design input requirements and the product meets its intended use.” However, your firm failed to establish the procedure as follows:\na. Your firm failed to adequately conduct design validation for the (b)(4) biopsy tools, such as (b)(4), listed on page 23 of IFU Rev J, Effective Date: 09\u002F25\u002F2024. During design validation, your firm only performed design validation for the (b)(4) and used the (b)(4) as the worst-case tool for biopsy tool passage. Furthermore, your firm only tested biopsy tool passage in a (b)(4) configuration of the bronchoscope instead of (b)(4) configuration to account for bending of the bronchoscope. Your firm initiated CAPA 24-007 after the complaint trend associated with biopsy tools not passing through working channel “exceeded the required action threshold.”\nb. Your procedure failed to define the requirements to test sterility as part of the shelf-life validations. Your bronchoscopes are sold as sterile with an expiration date of two years, but your firm did not test product sterility as part of the shelf-life validations in the following protocols:\ni. Protocol #TP-008, Revision E, describing the (b)(4) aging study, titled: “Galaxy Bronchoscope Verification Test Plan” and Summary Report #TR-087, Revision C.\nii. Protocol #TP-008, Revision E, describing the (b)(4) aging study, titled: “Galaxy Bronchoscope Verification Test Plan,” and Summary Report WP-16128A, Date Reviewed 05\u002F08\u002F2024.\niii. Protocol #TP-099, Revision B, relating to the (b)(4) aging study, titled: “Design Verification Protocol for Bronchoscope Packaging (includes (b)(4) and (b)(4) configurations)” and Summary Report #TR-378, Revision A.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-016 and CAPA 24-018. You indicate “as part of the Corrective Action, all instances of Design Verification and Validation of Requirements are being reviewed and where assumptions were made, these are being tested against documented evidence” (your firm’s response dated January 21, 2025). The CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\n4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\nSpecifically, your procedure, “Nonconforming Material,” (SOP-018 Rev. G, Effective Date: 09\u002F24\u002F2024,), has not been adequately implemented. Your firm failed to conduct investigations to identify the root cause(s) as required by your nonconforming material procedure. For example:\na. NCR 0367 (Dated 04\u002F11\u002F2024) involves (b)(4) bronchoscopes failing leak test due to (b)(4) in the working channels (part (b)(4)). However, your firm did not conduct investigation to identify the root cause(s) of the (b)(4) nor implement a SCAR with your supplier.\nb. NCR 0605 (Dated 09\u002F20\u002F2024) involves (b)(4) bronchoscopes failing leak tests. One failure was due to the working channel not adequately bonded to the (b)(4), and the other (b)(4) failures were due to (b)(4). However, your firm did not conduct investigation to identify the root cause(s) for the inadequate bonding nor the exposed (b)(4).\nc. NCR 0071 (Dated 07\u002F27\u002F2023) involves (b)(4) working channels found to have kinks. However, your firm failed to investigate to identify the root cause(s) for the kinks nor implement a SCAR with your supplier.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-021. Your responses indicate that your firm plans to update your procedures, conduct training once the revised procedures are complete, and address immediate issues including review of all NCRs to date (starting from May 2023, approximately (b)(4) NCRs) and identify those which require investigation or revisions. Also, you indicate that there was immediate containment for the NCRs cited during the recent inspection and your firm issued SCAR number 24-010 to your supplier to determine the root cause of working channel defects. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\n5. Failure to establish and maintain procedures for rework, to include retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications, as required by 21 CFR 820.90(b)(2). Rework and reevaluation activities, including a determination of any adverse effect from the rework upon the product, shall be documented in the device history record (DHR), as required by 21 CFR 820.90(b)(2).\nSpecifically, your procedure, “Rework and Deviation,” (SOP-020 Rev. B, Effective Date: 11\u002F28\u002F2022), has not been adequately established. For example, your Rework and Deviation procedure failed to include the requirement for determining whether there has been any adverse effect from rework upon the product when documenting rework and reevaluation activities. For example, the DHR for “Galaxy, Cart, (b)(4)” CRB-1516 (part number (b)(4)), relates to nonconformance #108, which described a nonconformance with an instrument driving mechanism ((b)(4)) on the Galaxy System robot. This nonconformance resulted in frozen bronchoscope camera images. The (b)(4) were replaced. However, your firm did not document a determination of whether there has been any adverse effect from reworking the (b)(4) upon the “Galaxy, Cart, (b)(4)” CRB-1516.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-022. Your responses indicate that you have revised your Rework and Deviation procedure and plan to conduct “a retrospective review of NCRs, rework, complaints and field repairs for all shipped systems to date as well as those in inventory to determine if any adverse effects are evident, and plan to implement corrections” (your response dated January 21, 2025). However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\nOur inspection also revealed that your firm’s Galaxy Systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the devices that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\nFailure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\nFor example, the information included for Complaint #00003935 and #00003614 reasonably suggests that during a procedure where your firm’s Galaxy System was used, the patients sustained injuries resulting in bleeding that were treated with irrigation and suction (Complaint #00003935) and Levophed administration (Complaint #00003614). We determined that these interventions were necessitated to prevent permanent impairment of a body function or permanent damage to a body structure (21 CFR 803.3(w)(3)). Your firm became aware of Complaint #00003935 on August 21, 2024, and FDA has not yet received an MDR for the corresponding MDR reportable event.\nYour firm became aware of Complaint #00003614 on July 24, 2024. Although the corresponding MDR #3021325287-2024-00024 was received by FDA on January 13, 2025, it was received beyond the 30-calendar-day timeframe.\nThe adequacy of your firm’s responses cannot be determined at this time. The responses indicate that your firm initiated a root cause investigation, plans to streamline its MDR reporting process, and is conducting a retrospective review of complaints for reportability. However, in the responses, your firm did not include documentation or evidence to demonstrate that the systemic corrective actions have been fully implemented, as these efforts are still ongoing.\nOur inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, the document titled “Medical Device Reporting,” Doc# SOP-026, Rev. C, dated 10\u002F28\u002F2024, was presented as your firm’s written MDR procedure. After reviewing the MDR procedure, the following deficiencies were noted:\nThe procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits the definitions of the terms “caused or contributed” from 21 CFR 803.3 and “reasonably suggests” found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nYour firm’s responses did not address the noted procedural deficiencies, as these were not included in the FDA Form 483.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: cdrhenforcement@fda.hhs.gov. Please include in the subject line, CMS case #702414 when replying. If you have any questions about the contents of this letter, please contact: Linda Linh Adams, Compliance Officer, at lindalinh.adams@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCc: Sam Mostafavi, Regulatory Advisor\u002F Management Representative, at sammostafavi@noahmed.com\n_______________________\n1 FDA also received a response dated February 18, 2025. This letter does not address that response given timing considerations. That response will be considered along with any response to this letter.\n2 Under 21 CFR 820.3(k), “establish” means define, document (in writing or electronically), and implement.","Noah Medical Corporation","noah-medical-corporation-702414-04092025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnoah-medical-corporation-702414-04092025","2026-10-26T08:09:34.20429+00:00","Warning Letter","Issued","2025-04-22","702414","Medical Devices","Jian Zhang","2026-08-19T16:52:23.305+00:00","VIA Electronic Mail","2025-04-09",{"id":32,"raw":33,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":18,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":52,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},630,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-04T04:00:00Z\">09\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnuvida-medical-llc-707745-09042025\">NuVida Medical LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-707745\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Park Thomas\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer and Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>NuVida Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5814 S 25th St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85040\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:park.thomas@nuvidamed.com\"> park.thomas@nuvidamed.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 04, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 25-707745\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Thomas:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between February 10, 2025, and February 19, 2025. During the inspection, FDA documented that your company distributes two products derived from human amniotic membrane, Procenta and XCELLERATE; a product consisting of three layers of the placental membrane including amnion (amniotic membrane), chorion (chorionic membrane), and the intermediate layer, completeFT\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>; and a product derived from human dermal tissue, Coll-E-Derm, for allogeneic use (collectively, “your products”).\u003C\u002Fp>\u003Cp>This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your website https:\u002F\u002Fnuvidamed.com\u002F and the website https:\u002F\u002Fextremitycare.com\u002F linked to your website for more information about your products (last visited September 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\u003C\u002Fp>\u003Cul>\u003Cli>Procenta, XCELLERATE, and completeFT are each described on the website https:\u002F\u002Fextremitycare.com, linked to on your https:\u002F\u002Fnuvidamed.com website, as “a placental tissue allograft that may be used as a protective barrier in wound care applications. The natural properties of amniotic tissue provide mechanical protection and growth factors to support the management of acute and chronic wounds.”\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fli>\u003Cli>Coll-e-Derm is described on the website https:\u002F\u002Fextremitycare.com, linked to on your https:\u002F\u002Fnuvidamed.com website, as “a prehydrated human acellular dermal matrix that retains angiogenin and collagen type IV. Angiogenin and collagen type IV may play a key role in supporting revascularization.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your Procenta, XCELLERATE, completeFT, and Coll-e-Derm products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Nuvida Medical LLC does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your Procenta, XCELLERATE, completeFT, and Coll-e-Derm products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). In the donor, amniotic membrane and placental membrane comprising all three layers (amnion, intermediate layer, and chorion) serve as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero. The labeling, advertising, and other indications of your objective intent demonstrate that Procenta, XCELLERATE, and completeFT are intended to perform functions that are not considered the same basic function or functions in the recipient as in the donor. Rather, your Procenta, XCELLERATE, and completeFT products are intended for certain wound care applications, including by providing growth factors,\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> that fall outside of the basic function of amniotic membrane and placental membrane comprising all three layers (amnion, intermediate layer, and chorion) in the donor. Therefore, Procenta, XCELLERATE, and completeFT fail to meet the criterion for homologous use (21 CFR 1271.10(a)(2)).\u003C\u002Fp>\u003Cp>With respect to your Coll-e-Derm™ product, skin in the donor serves to provide covering, protecting the body from external force, and serving as a water-resistant barrier to pathogens or other damaging agents in the external environment. The labeling, advertising, and other indications of your objective intent demonstrate that your Coll-e-Derm™ product is intended to perform functions that are not considered the same basic function or functions in the recipient as in the donor. Rather, your Coll-e-Derm™product is intended for use in “supporting revascularization.” Supporting revascularization is not a basic function of dermal tissue in the donor. Supporting revascularization would require biochemical stimulation of a wound healing response in the body via cell signaling, which is not a basic function of dermal tissue in the donor. Therefore, your Coll-e-Derm™ product fails to meet the criterion for homologous use (21 CFR 1271.10(a)(2)).\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Response to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your response, dated March 12, 2025, to FDA’s Form FDA-483 in detail. We acknowledge your representation that you have corrected the deficiencies documented on the FDA-483. We also acknowledge that you removed certain claims regarding your products from your website based on discussions with the FDA investigator concerning the intended uses of your products. Your voluntary corrections were not sufficient to correct the violations noted in this letter, because your products continue to be intended for non-homologous uses.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter addresses certain issues regarding your products and is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. We advise you to comprehensively review your website and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&amp;C Act, the PHS Act, and their implementing regulations. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003Cbr>\u003Cbr>Cc:&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Oliver Burckhardt\u003Cbr>Chief Operating Officer and Owner\u003Cbr>Extremity Care LLC\u003Cbr>555 E North Ln\u003Cbr>Ste 5000, Bldg D\u003Cbr>Conshohocken, PA 19428\u003C\u002Fp>\u003Cp>Leonard R. Duford\u003Cbr>President and Chief Executive Officer\u003Cbr>Lucina BioSciences, LLC\u003Cbr>14707 E 2nd Ave GL150\u003Cbr>Aurora, CO 80011\u003C\u002Fp>\u003Cp>_______________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> You also market completeFT as an “collagenous amnion\u002Fchorion memrane allograft...derived from placental tissue” and a “full thickness amniotic membrane.”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Your product provides growth factors but it is unclear how growth factors would support wound management (such as covering\u002Fprotecting the wound or providing a moist wound environment) as opposed to wound healing.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> As stated above, it is unclear how the growth factors in your products would support wound management as opposed to wound healing. Wound healing is not a basic function of amniotic membrane or placental membrane comprising all three layers (amnion, intermediate layer, and chorion).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 25-707745\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nPark Thomas\n\nRecipient Title\n\nChief Executive Officer and Owner\n\nNuVida Medical LLC\n\n5814 S 25th St\n\nPhoenix, AZ 85040\n\nUnited States\n\npark.thomas@nuvidamed.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nSeptember 04, 2025\nCBER 25-707745\nDear Mr. Thomas:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between February 10, 2025, and February 19, 2025. During the inspection, FDA documented that your company distributes two products derived from human amniotic membrane, Procenta and XCELLERATE; a product consisting of three layers of the placental membrane including amnion (amniotic membrane), chorion (chorionic membrane), and the intermediate layer, completeFT1; and a product derived from human dermal tissue, Coll-E-Derm, for allogeneic use (collectively, “your products”).\nThis letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nBased on information and records reviewed by FDA, including your website https:\u002F\u002Fnuvidamed.com\u002F and the website https:\u002F\u002Fextremitycare.com\u002F linked to your website for more information about your products (last visited September 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\nProcenta, XCELLERATE, and completeFT are each described on the website https:\u002F\u002Fextremitycare.com, linked to on your https:\u002F\u002Fnuvidamed.com website, as “a placental tissue allograft that may be used as a protective barrier in wound care applications. The natural properties of amniotic tissue provide mechanical protection and growth factors to support the management of acute and chronic wounds.”2\nColl-e-Derm is described on the website https:\u002F\u002Fextremitycare.com, linked to on your https:\u002F\u002Fnuvidamed.com website, as “a prehydrated human acellular dermal matrix that retains angiogenin and collagen type IV. Angiogenin and collagen type IV may play a key role in supporting revascularization.”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour Procenta, XCELLERATE, completeFT, and Coll-e-Derm products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Nuvida Medical LLC does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your Procenta, XCELLERATE, completeFT, and Coll-e-Derm products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). In the donor, amniotic membrane and placental membrane comprising all three layers (amnion, intermediate layer, and chorion) serve as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero. The labeling, advertising, and other indications of your objective intent demonstrate that Procenta, XCELLERATE, and completeFT are intended to perform functions that are not considered the same basic function or functions in the recipient as in the donor. Rather, your Procenta, XCELLERATE, and completeFT products are intended for certain wound care applications, including by providing growth factors,3 that fall outside of the basic function of amniotic membrane and placental membrane comprising all three layers (amnion, intermediate layer, and chorion) in the donor. Therefore, Procenta, XCELLERATE, and completeFT fail to meet the criterion for homologous use (21 CFR 1271.10(a)(2)).\nWith respect to your Coll-e-Derm™ product, skin in the donor serves to provide covering, protecting the body from external force, and serving as a water-resistant barrier to pathogens or other damaging agents in the external environment. The labeling, advertising, and other indications of your objective intent demonstrate that your Coll-e-Derm™ product is intended to perform functions that are not considered the same basic function or functions in the recipient as in the donor. Rather, your Coll-e-Derm™product is intended for use in “supporting revascularization.” Supporting revascularization is not a basic function of dermal tissue in the donor. Supporting revascularization would require biochemical stimulation of a wound healing response in the body via cell signaling, which is not a basic function of dermal tissue in the donor. Therefore, your Coll-e-Derm™ product fails to meet the criterion for homologous use (21 CFR 1271.10(a)(2)).\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.4 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nResponse to the Form FDA-483\nWe have reviewed your response, dated March 12, 2025, to FDA’s Form FDA-483 in detail. We acknowledge your representation that you have corrected the deficiencies documented on the FDA-483. We also acknowledge that you removed certain claims regarding your products from your website based on discussions with the FDA investigator concerning the intended uses of your products. Your voluntary corrections were not sufficient to correct the violations noted in this letter, because your products continue to be intended for non-homologous uses.\nConclusion\nThis letter addresses certain issues regarding your products and is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. We advise you to comprehensively review your website and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&C Act, the PHS Act, and their implementing regulations. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n\nCc:\n(b)(4)\nOliver Burckhardt\nChief Operating Officer and Owner\nExtremity Care LLC\n555 E North Ln\nSte 5000, Bldg D\nConshohocken, PA 19428\nLeonard R. Duford\nPresident and Chief Executive Officer\nLucina BioSciences, LLC\n14707 E 2nd Ave GL150\nAurora, CO 80011\n_______________________________\n1 You also market completeFT as an “collagenous amnion\u002Fchorion memrane allograft...derived from placental tissue” and a “full thickness amniotic membrane.”\n2 Your product provides growth factors but it is unclear how growth factors would support wound management (such as covering\u002Fprotecting the wound or providing a moist wound environment) as opposed to wound healing.\n3 As stated above, it is unclear how the growth factors in your products would support wound management as opposed to wound healing. Wound healing is not a basic function of amniotic membrane or placental membrane comprising all three layers (amnion, intermediate layer, and chorion).\n4 Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","NuVida Medical LLC","nuvida-medical-llc-707745-09042025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnuvida-medical-llc-707745-09042025","2026-10-26T08:09:36.196341+00:00","2025-09-16","707745","Biologics","Park Thomas","2026-08-19T16:24:00.321+00:00","Via UPS and EMAIL","CBER 25-707745","2025-09-04",{"id":55,"raw":56,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":23,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":19,"issuing_office":60,"recipient_name":19,"body_fetched_at":72,"delivery_method":73,"recipient_title":19,"reference_number":19,"action_taken_date":74,"medical_device_id":19,"response_letter_date":19},472,[57,58,59,60,61,13,13,13],"\u003Ctime datetime=\"2025-11-18T05:00:00Z\">11\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-13T05:00:00Z\">11\u002F13\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025\">Medical Mega\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Medical Mega\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>208 Fairmont Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jersey City\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07306\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Sales@medicalmega.com\"> Sales@medicalmega.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 13, 2025\u003C\u002Fp>\u003Cp>RE: 717840\u003C\u002Fp>\u003Cp>Medical Mega:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\u003C\u002Fp>\u003Cp>With respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&amp;C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\u003C\u002Fp>\u003Cp>Therefore, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&amp;C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\u003Cp>In addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&amp;C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nMedical Mega\n\n208 Fairmont Ave\n\nJersey City, NJ 07306\n\nUnited States\n\nSales@medicalmega.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nNovember 13, 2025\nRE: 717840\nMedical Mega:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\n“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\nBased on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\nWith respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\nTherefore, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\nIn addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_________________\n1 On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).","Medical Mega","medical-mega-717840-11132025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025","2026-10-26T08:09:22.956521+00:00","2025-11-18","717840","Drugs","2026-08-19T14:27:25.954+00:00","Via Email","2025-11-13",{"id":76,"raw":77,"subject":81,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":66,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":89,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":90,"body_fetched_at":91,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":92,"medical_device_id":19,"response_letter_date":19},266,[78,79,80,11,81,13,13,13],"\u003Ctime datetime=\"2026-03-17T04:00:00Z\">03\u002F17\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-03T04:00:00Z\">09\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Favertix-medical-inc-711080-09032025\">Avertix Medical, Inc.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Timothy P. Moran\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Avertix Medical, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>40 Christopher Way, Ste 201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Eatontown\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07724\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:tmoran@avertix.com\"> tmoran@avertix.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 711080\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 3, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Moran:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Eatontown, NJ from February 19, 2025, through March 11, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures The Guardian System, an implantable coronary syndrome event detector. The Guardian System consists of three main system components: an implantable device used to monitor a patient’s electrogram (IMD); a hand-held telemetry device that provides alarms and alerts and interfaces between the IMD and programmer (EXD); and a programmer utilized by healthcare professionals to program the IMD and alarm\u002Falert settings and retrieve and review IMD data (Programmer). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received responses from David Keenan, Chief Technology Officer, dated March 31, 2025, and June 20, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to maintain complaint files; and failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198(a). Specifically, the firm’s procedure, Complaint Procedure, #1716-002, Rev Q (dated February 25, 2022) to Rev R (dated April 11, 2022) has not been adequately established in that:\u003C\u002Fp>\u003Cp>a. Your firm failed to adequately maintain complaint files, as required by 21 CFR 820.198(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, section 5.1.2 of your complaint procedure requires all employees to report any product complaint or feedback from the field. Section 5.1.3 of the complaint procedure covers the review of “ISSUES” to disposition them as a “COMPLAINT” or “REJCT\u002FNo ACTION REQUIRED”. The FDA investigator identified 11 issues which meet the definition of a complaint and were not dispositioned as a complaint as required by your procedure. For example:\u003C\u002Fp>\u003Cp>i. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reported on November 6, 2023, listing the patient effect description as “Guardian Device was removed from the patient due to a recurrent pocket infection post implant.”\u003C\u002Fp>\u003Cp>ii. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reported on March 4, 2022, listed the programmer battery connector broke when trying to remove the battery.\u003C\u002Fp>\u003Cp>iii. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reported on September 6, 2023, listed the USB Drive for Programmer was not connected and required formatting each time to use.\u003C\u002Fp>\u003Cp>Additionally, six of eleven “nonconforming material reports” (NCMRs) reviewed during the inspection that met the definition of complaints were not considered complaints and as such were handled according to your nonconforming material process. For example:\u003C\u002Fp>\u003Cp>iv. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, created April 30, 2024, states that a Programmer (PROG-003) was returned from the field due to issues with the battery charging indicator light.\u003C\u002Fp>\u003Cp>v. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, created September 6, 2023, states a USB flash drive was not functioning properly in the field and was returned.\u003C\u002Fp>\u003Cp>vi. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, created November 22, 2022, states that a field clinical engineer reported that a Programmer Battery was damaged while being inserted into the Programmer.\u003C\u002Fp>\u003Cp>The above “issues” and “nonconforming product reports” were not evaluated for MDR reportability and were not reviewed to determine if an investigation is necessary, since they were not considered complaints.\u003C\u002Fp>\u003Cp>b. Your firm failed to adequately establish and maintain procedures to ensure that all complaints are processed in a uniform and timely manner, as required by 21 CFR 820.198(a)(1).\u003C\u002Fp>\u003Cp>Specifically, your firm’s \u003Cem>Complaint Procedure\u003C\u002Fem>, #1716-002, does not include a requirement for timely and uniform complaint handling. For example, the following complaints were entered as issues and were not escalated to complaints in a timely manner:\u003C\u002Fp>\u003Cp>i. Complaint-00077: On July 17, 2024, your firm became aware of a reported issue where the physician was unable to retrieve data from the IMD implant. The complaint record was not opened until September 5, 2024 (50 days after becoming aware).\u003C\u002Fp>\u003Cp>ii. Complaint-00066: On February 13, 2024, your firm became aware of an IMD explant due to an infection. The complaint record was not opened until March 28, 2024 (44 days after becoming aware).\u003C\u002Fp>\u003Cp>iii. Complaint-00059: On November 30, 2023, your firm became aware of a reported “flat line IMD” event. The complaint record was not opened until January 5, 2024 (36 days after becoming aware).\u003C\u002Fp>\u003Cp>iv. Complaint-00039: On October 28, 2022, your firm became aware of an IMD explant due to an infection. The complaint record was not opened until December 1, 2022 (34 days after becoming aware).\u003C\u002Fp>\u003Cp>c. Your firm failed to review, evaluate, and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820 820.198(c).\u003C\u002Fp>\u003Cp>Specifically, Section 5.1.4 of your \u003Cem>Complaint Procedure\u003C\u002Fem> requires investigation of complaints. Your firm failed to adequately review, evaluate, and investigate the following complaints that reported patient infection and subsequent explant of the implantable cardiac monitoring device (IMD), the implantable portion of The Guardian System:\u003C\u002Fp>\u003Cp>i. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reported on February 13, 2024, that subsequently became Complaint-00066, documents the justification for not performing an investigation as: “\u003Cem>Physician determined patient had a pocket infection and made the decision to explant and device. No investigation needed\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>ii. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reported on October 28, 2022, that subsequently became Complaint-00039, documents the “Initiate Investigation Process” option was selected but no investigation was performed and the “\u003Cem>Review for Closure\u003C\u002Fem>” section of the complaint records lists “\u003Cem>no investigation needed\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. In the response, your firm states that CAPA 00015 was opened to capture all corrective and preventive work performed in relation to this observation. As part of CAPA 00015, your firm promised to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm also promised to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, the response does not address performing a retrospective review of all issues and nonconforming product reports to determine if other complaints exist and if investigations need to be performed. Several of the items promised by your firm continue to be in-progress (including but not limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR 820.90(a).\u003C\u002Fp>\u003Cp>Specifically, your \u003Cem>Nonconformance Material Procedure\u003C\u002Fem>, #1707-002, does not include a provision for the determination of the need for an investigation. For example, the following two nonconformances did not include a documented investigation or evaluation:\u003C\u002Fp>\u003Cp>a. \u003Cstrong>(b)(4)\u003C\u002Fstrong> was created on June 27, 2024, for IMD batteries that were sent to your contract manufacturer for use in production were returned due to nonconformances (bent prongs). The disposition of the batteries was recorded as being scrapped. However, there was no investigation conducted into the cause of the bent probes and the nonconformance record does not include a rationale for not investigating.\u003C\u002Fp>\u003Cp>b. \u003Cstrong>(b)(4)\u003C\u002Fstrong> was created on June 7, 2023, for the EXD-001 Battery Packaging Label (p\u002Fn \u003Cstrong>(b)(4)\u003C\u002Fstrong>) on the EXD-001 Battery, 10 Packs (p\u002Fn \u003Cstrong>(b)(4)\u003C\u002Fstrong>) listing an incorrect expiration date and battery lot code in finished goods inventory. Your firm reworked the nonconforming product. However, there was no investigation conducted into the cause of the incorrect labeling and the nonconformance record does not include a rationale for not investigating.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Your response promises to \u003Cstrong>(b)(4)\u003C\u002Fstrong> as well as plans to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. All activities are captured in CAPA 00017 and all work is promised by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your response fails to address if a retrospective review of NCMRs will be conducted. Several of these promised actions (including CAPA 00017) remain in-progress with a tentative CAPA Effectiveness Verification planned due date of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish and maintain procedures for validating the device design to include adequate risk analysis, as required by 21 CFR 820.30(g). Specifically, section 6.14 of your \u003Cem>Risk Management Procedure\u003C\u002Fem>, #1701-011, covers the information collection, information review, and actions related to the use of the Corrective and Preventive Action System and the Complaint System to monitor the device in the clinical and post-production phase to determine if reassessment of risks and\u002For assessment of new risks is necessary. Your firm failed to reassess the risk when estimated risks from a hazard differed from the actual risk observed in post-market CAPA and complaint data. For example:\u003C\u002Fp>\u003Cp>a. Your firm has received three complaints of infection with the IMD portion of the Guardian System out of a total of \u003Cstrong>(b)(4)\u003C\u002Fstrong> IMDs implanted as of February 25, 2025. The observed rate of infection is \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. In your device risk file, \u003Cem>Guardian System Risk Assessment\u003C\u002Fem> – P18, #0201-0200-001#P18, Rev B, dated November 13, 2023, the rate of infection was estimated to be \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. The risk was not reassessed.\u003C\u002Fp>\u003Cp>b. Your firm has received 24 complaints of battery failure due to electrical short before the device reached its expected service life of 6 years, causing patients to opt for early explant and\u002For replacement. The observed rate of battery failure is \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. In your device risk file, \u003Cem>IMD AMSG3-E Hardware FMECA Report – P16\u003C\u002Fem>, #0212-0201-001#P16, Rev A; dated February 24, 2015, the rate of battery failure was estimated to be \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Further, your firm initiated CAPA-00012 in response to the battery failures. The “Process Impacts” section of this CAPA indicates that no updates to risk management were needed. The risk was not reassessed.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. In the response, your firm indicates that CAPA 00016 was opened to address any corrective and preventive work taken as result of the observation including to assess the risk associated with infection using current performance data against historical data and to address the need to perform risk reviews on a regularly scheduled basis to keep the risk data current by July 1, 2025. However, your firm did not indicate if you intend to review, and update as necessary, the risk file utilizing post-market data for items other than risk of infection. Several of the items promised by your firm continue to be in-progress, including but not limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong> which has a \u003Cstrong>(b)(4)\u003C\u002Fstrong> planned due date of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm failed to follow your procedure, Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, when taking corrective and preventive actions. Two examples of lack of CAPA procedure implementation are as follows:\u003C\u002Fp>\u003Cp>a. Your firm failed to follow your CAPA process for a corrective action taken as a result of a consumer complaint which led to a revision made to manufacturing procedure Process Specification, PROG-004 Final Shipping Manufacturing, #0217-1200-020#P18, Rev F, dated November 19, 2024. These actions were taken outside of the CAPA system and lack a documented CAPA investigation as well as verification of implementation and effectiveness.\u003C\u002Fp>\u003Cp>b. Your firm failed to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). Specifically, section 5.9 of the Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, describes your firm’s process for establishing verification of effectiveness plans with predetermined criteria that verify if corrective and\u002For preventive actions were effective. Additionally, section 5.10 of the Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, describes the process for conducting the verification of effectiveness (VOE) phase to demonstrate effectiveness.\u003C\u002Fp>\u003Cp>Review of five CAPAs closed between January 2022 and the time of the current inspection disclosed that four CAPAs (CAPA-00007, CAPA-00008, CAPA-00010, and CAPA-00014) lacked evidence that your firm verified or validated that the action taken was effective.\u003C\u002Fp>\u003Cp>For example, CAPA-00007, was opened as a result of the previous inspection on March 15, 2022, related to a complaint involving EXD batteries having expired shelf life. Your firm implemented several corrective actions to correct the issue which were documented utilizing the complaint record (complaint number 00013) instead of through the CAPA system. CAPA-00007 was closed on March 31, 2022, without verifying the effectiveness of the correction and preventive actions taken.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. In this response, your firm opened CAPA 00016 to document actions taken for this observation. Your firm promises to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For the 5 CAPAs lacking VOE plans and reports, your firm asks our Agency if \u003Cstrong>(b)(4)\u003C\u002Fstrong> (2021 or earlier). The decision to \u003Cstrong>(b)(4)\u003C\u002Fstrong> remains your firm’s decision as long as it is based on a rationale you determine to be appropriate given the 21 CFR 820.100(a)(4) and your own procedural requirement to demonstrate effectiveness of a CAPA action. You are also going to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response does not address if other CAPAs will be reviewed to determine if \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Several of the items promised by your firm continue to be in-progress (including but not limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>5. Failure to validate with a high degree of assurance and approve according to established procedures, a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). Specifically, your firm’s Process Validation Procedure, #1705-002, Rev E, dated October 23, 2020, and Process Qualification Procedure, #1705-001, Rev F, dated October 23, 2020, were not adequately established in that both procedures fail to address sterilization validation. Your firm’s implantable cardiac monitoring device (IMD) undergoes \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization. Further, the two procedures fail to document the process of requalification and revalidation (if necessary) of the sterilization cycle.\u003C\u002Fp>\u003Cp>For example, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process for your firm’s IMD was last performed in June 2022 by a 3rd party in accordance with FDA-recognized standard ANSI\u002FAAMI\u002FISO 11135:2014. Your firm has not reviewed the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process since the 2022 requalification.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. In the responses, you indicate that CAPA 00019 was opened as a result of the observation and that your firm promises to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your responses do not address if your firm’s plans to revise your process validation procedures to include sterilization. Additionally, supporting evidence (including CAPA 00019) of these promised actions remain in progress with a CAPA Effectiveness Verification planned due date for CAPA 00019 of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>6. Failure to adequately establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants, as required by 21 CFR 820.50(a). Specifically, your \u003Cem>Supplier Management Procedure\u003C\u002Fem> (#1703-003), has not been fully implemented. For example:\u003C\u002Fp>\u003Cp>a. Your firm’s \u003Cem>Supplier Management Procedure\u003C\u002Fem> (#1703-003) describes a process for supplier evaluation and acceptance using a supplier evaluation form. The Supplier Evaluation Form for the IMD battery supplier, (dated February 13, 2020), indicated your firm’s contract manufacturer would perform receiving inspections of these batteries and provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> to Avertix. Your QA\u002FQC manager stated these \u003Cstrong>(b)(4)\u003C\u002Fstrong> were not completed.\u003C\u002Fp>\u003Cp>b. Your firm failed to adequately establish and maintain records of acceptable suppliers, contractors, and consultants, as required by 21 CFR 820.50(a)(3). Specifically, section 7.1.12 of Supplier Management Procedure, Rev K, states that “Quality Assurance is responsible for revising the Approved Supplier List with changes made based on acceptance\u002Frejection of potential suppliers\u002Fre-evaluated suppliers\u002Fdeactivated suppliers…” A software supplier used by your firm since 2023 to meet the requirements of the Medical Device Tracking regulation was not listed on your Approved Supplier List (Rev L, dated June 15, 2023).\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. In the responses, your firm promises and provided revisions to your Supplier Management Procedure (Document 1703-003) removing the requirement for \u003Cstrong>(b)(4)\u003C\u002Fstrong> for your contract manufacturer and to evidence of a new supplier evaluation for the software supplier utilized for medical device tracking by July 1, 2025. The responses do not indicate if other supplier evaluations will be evaluated and updated, as needed. Further, CAPA 00023 remains in progress with a CAPA Effectiveness Verification planned due date of December 1, 2025.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Guardian System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 803 - Medical Device Reporting was promulgated under section 519 of the Act, among other provisions. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to report to the FDA the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fp>\u003Cp>For example, the information included for Complaint-00066, Issue-00091, and Complaint-00039 reasonably suggests that each patient sustained an injury or illness (i.e., infection) following implantation of your firm’s Guardian System. These infections constituted serious injuries within the meaning of 21 CFR 803.3(w) because they necessitated surgical intervention (i.e., explantation) to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of information that reasonably suggests that the Guardian System may have caused or contributed to a serious injury on February 13, 2024, for Complaint-00066, on November 6, 2023, for Issue-00091, and on October 28, 2022, for Complaint-00039. As such, Complaint-00066, Issue-00091, and Complaint-00039 represent MDR reportable events, as defined in 21 CFR 803.3(o)(2)(i). However, the FDA did not receive an MDR for each referenced event until April 10, 2025, which exceeded the required 30 calendar day reporting timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. We acknowledge that the FDA received the manufacturer reports, submitted using the electronic equivalent of Form 3500A, for the referenced serious injury events after the 30 calendar day reporting timeframe had elapsed. However, although the response referenced the updated MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, as part of its correction action for the late reporting issue, a copy of the updated MDR procedure was not included.\u003C\u002Fp>\u003Cp>2. Failure to report to the FDA the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\u003Cp>For example, the information included for Complaints No. 00057, 00065, 00070, 00071, 00072, 00074, 00077, 00079, 00080, 00082, 00083, and 00086, reasonably suggests that your firm’s Guardian System malfunctioned while in use. Specifically, the device prematurely reached its end of service due to early battery depletion, meaning that it failed to meet its performance specifications or otherwise perform as intended under 21 CFR 803.3(k). Your firm initiated recall Z-1140-2025 for the referenced malfunction. A malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the Act as a result of the malfunction of the device or other similar devices. See Medical Devices; Medical Device User Facility and Manufacturer Reporting, Certification and Registration, 60 Fed. Reg. 63585 (Dec. 11, 1995) (referring to section 519(f), which has since been redesignated as section 519(g)). As such, the referenced complaints represent MDR reportable events, as defined under 21 CFR 803.3(o)(2)(ii).\u003C\u002Fp>\u003Cp>Your firm became aware of information on the following dates that reasonably suggests that the Guardian System had malfunctioned and this device or a similar device your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur: October 10, 2023, for Complaint No. 00057; February 26, 2024, for 00065; May 28, 2024, for 00070; May 14, 2024, for 00071; May 5, 2024, for 00072; May 14, 2024, for 00074; July 17, 2024, for 00077; August 29, 2024, for 00079; August 21, 2024, for 00080; November 19, 2024, for 0008; November 19, 2024, for 00083; and December 3, 2024, for 00086. Your firm submitted a report for each event using the MedWatch Online Voluntary Reporting Form. Specifically, MW5149541 (Complaint No. 00057), MW5153561 (Complaint No. 00065), MW5159171 (Complaint No. 00070), MW5159172 (Complaint No.00071), MW5159173 (Complaint No. 00072), MW5159805 (Complaint No. 00074), MW5160629 (Complaint No. 00077), MW5160632 (Complaint No. 00079), MW5160633 (Complaint No. 00080), MW5164478 (Complaint No. 00082), MW5164476 (Complaint No. 00083), and MW5164481 (Complaint No. 00086). The submission of reports using the voluntary MedWatch Online Voluntary Reporting Form does not fulfill reporting obligations arising under 21 CFR Part 803. An electronic submission of a mandatory report from a manufacturer must contain the information from the applicable blocks of Form FDA 3500A. All medical device reports must be submitted within the required timeframes. However, the FDA did not receive the corresponding MDRs until April 14, 2025, which exceeded the required 30 calendar day reporting timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. We acknowledge that the FDA received the manufacturer reports, submitted using the electronic equivalent of Form 3500A, for the referenced malfunction events based on your firm’s retrospective review on April 14, 2025, after the 30 calendar day reporting timeframe had elapsed.\u003C\u002Fp>\u003Cp>However, although the response referenced the updated MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, as part of its correction action for the late reporting issue, a copy of the updated MDR procedure was not included.\u003C\u002Fp>\u003Cp>In addition, the inspection revealed that your firm failed to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, your firm presented the document titled “Medical Device Vigilance Procedures,” Document No. 1716-005, Rev. F, dated June 25, 2024, as its MDR procedure. Upon review, we conclude that the MDR procedure does not develop, maintain, and implement written MDR procedures for internal systems that provide for timely transmission of complete medical device reports to FDA, as required by 21 CFR 803.17(a)(3). Specifically, the procedure 1716-005, Rev. F does not include instructions for how your firm will comply with the 21 CFR 803.12(a) requirement to submit reports to FDA in an electronic format that FDA can process, review, and archive. As a manufacturer, you must submit reports of individual adverse events to FDA in an electronic format in accordance with 21 CFR 803.12(a) and 803.20, unless granted an exemption under 21 CFR 803.19.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. While your response included a copy of the updated Complaint Procedure, Document No.1716-002, and staff training records, it referenced an update to the MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, without including a copy. Without the referenced document, we cannot fully assess the adequacy of the response.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Guardian System Model AMSG3‐E IMD implant devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals was promulgated under section 519 of the Act, among other provisions. Violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit to the FDA within 10 working days of initiating a correction or removal a report required by 21 CFR 806.10.\u003C\u002Fp>\u003Cp>Specifically, on September 18, 2023, Avertix Medical, Inc., delivered a letter to physicians who have patients implanted with a Model AMSG3‐E IMD manufactured during the period when a contamination issue was occurring on the battery production line. This issue led to premature battery depletion in the Guardian System implants, which can result in failure to monitor and earlier‐than‐expected implant replacement surgery. The letter recommends reducing the interval of regular follow-up visits and reinforcing the patient training. FDA determined that shorter device implant life leading to sooner than expected replacement surgery may present a risk to health. This action constitutes a medical device correction or removal initiated to reduce a risk to health posed by the device or remedy a violation of the Act caused by the device which may present a risk to health under 21 CFR 806.10(a). Accordingly, you were required to submit a Report of Correction or Removal to FDA within 10 working days of initiation, under 21 CFR 806.10(b). You submitted a Medical Device Report of Correction or Removal to FDA for this action on December 11, 2024.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. The responses do not contain evidence that your firm’s procedures will result in compliance with the medical device correction and removal reporting requirements in 21 CFR 806. CAPA 00020 states that management failed to recognize that it needed to submit a Report of Correction or Removal within 10 working days of initiation. Your corrective action was retraining personnel in two procedures, Complaint Procedure (1716-002) and Vigilance Procedure (1716-005). You stated that your Quality Management System (QMS) procedure specifies that recalls or corrections must be reported within 10 days. However, your responses did not include a new revision of 1716-005 nor procedure 1716-004, PRODUCT RECALLS, CORRECTIONS AND REMOVALS. Procedure 1716-004 Rev F, collected in the inspection, notes that the Recall Coordinator is responsible for communicating with regulatory agencies within defined reporting times as per the Vigilance procedure. The procedure titled MEDICAL DEVICE VIGILANCE PROCEDURES, 1716-005 Rev F, collected during the inspection, does not describe Reports of Corrections or Removals, required by 21 CFR 806. Therefore, training personnel on 1716-005 will not help personnel know the timeframe for reporting a Medical Device Correction or Removal to FDA.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 711080” when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan, Compliance Officer at sean.moynihan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nTimothy P. Moran\n\nRecipient Title\n\nPresident and CEO\n\nAvertix Medical, Inc.\n\n40 Christopher Way, Ste 201\n\nEatontown, NJ 07724\n\nUnited States\n\ntmoran@avertix.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 711080\nSeptember 3, 2025\nDear Mr. Moran:\nDuring an inspection of your firm located in Eatontown, NJ from February 19, 2025, through March 11, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures The Guardian System, an implantable coronary syndrome event detector. The Guardian System consists of three main system components: an implantable device used to monitor a patient’s electrogram (IMD); a hand-held telemetry device that provides alarms and alerts and interfaces between the IMD and programmer (EXD); and a programmer utilized by healthcare professionals to program the IMD and alarm\u002Falert settings and retrieve and review IMD data (Programmer). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from David Keenan, Chief Technology Officer, dated March 31, 2025, and June 20, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to maintain complaint files; and failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198(a). Specifically, the firm’s procedure, Complaint Procedure, #1716-002, Rev Q (dated February 25, 2022) to Rev R (dated April 11, 2022) has not been adequately established in that:\na. Your firm failed to adequately maintain complaint files, as required by 21 CFR 820.198(a).\nSpecifically, section 5.1.2 of your complaint procedure requires all employees to report any product complaint or feedback from the field. Section 5.1.3 of the complaint procedure covers the review of “ISSUES” to disposition them as a “COMPLAINT” or “REJCT\u002FNo ACTION REQUIRED”. The FDA investigator identified 11 issues which meet the definition of a complaint and were not dispositioned as a complaint as required by your procedure. For example:\ni. (b)(4), reported on November 6, 2023, listing the patient effect description as “Guardian Device was removed from the patient due to a recurrent pocket infection post implant.”\nii. (b)(4), reported on March 4, 2022, listed the programmer battery connector broke when trying to remove the battery.\niii. (b)(4), reported on September 6, 2023, listed the USB Drive for Programmer was not connected and required formatting each time to use.\nAdditionally, six of eleven “nonconforming material reports” (NCMRs) reviewed during the inspection that met the definition of complaints were not considered complaints and as such were handled according to your nonconforming material process. For example:\niv. (b)(4), created April 30, 2024, states that a Programmer (PROG-003) was returned from the field due to issues with the battery charging indicator light.\nv. (b)(4), created September 6, 2023, states a USB flash drive was not functioning properly in the field and was returned.\nvi. (b)(4), created November 22, 2022, states that a field clinical engineer reported that a Programmer Battery was damaged while being inserted into the Programmer.\nThe above “issues” and “nonconforming product reports” were not evaluated for MDR reportability and were not reviewed to determine if an investigation is necessary, since they were not considered complaints.\nb. Your firm failed to adequately establish and maintain procedures to ensure that all complaints are processed in a uniform and timely manner, as required by 21 CFR 820.198(a)(1).\nSpecifically, your firm’s Complaint Procedure, #1716-002, does not include a requirement for timely and uniform complaint handling. For example, the following complaints were entered as issues and were not escalated to complaints in a timely manner:\ni. Complaint-00077: On July 17, 2024, your firm became aware of a reported issue where the physician was unable to retrieve data from the IMD implant. The complaint record was not opened until September 5, 2024 (50 days after becoming aware).\nii. Complaint-00066: On February 13, 2024, your firm became aware of an IMD explant due to an infection. The complaint record was not opened until March 28, 2024 (44 days after becoming aware).\niii. Complaint-00059: On November 30, 2023, your firm became aware of a reported “flat line IMD” event. The complaint record was not opened until January 5, 2024 (36 days after becoming aware).\niv. Complaint-00039: On October 28, 2022, your firm became aware of an IMD explant due to an infection. The complaint record was not opened until December 1, 2022 (34 days after becoming aware).\nc. Your firm failed to review, evaluate, and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820 820.198(c).\nSpecifically, Section 5.1.4 of your Complaint Procedure requires investigation of complaints. Your firm failed to adequately review, evaluate, and investigate the following complaints that reported patient infection and subsequent explant of the implantable cardiac monitoring device (IMD), the implantable portion of The Guardian System:\ni. (b)(4), reported on February 13, 2024, that subsequently became Complaint-00066, documents the justification for not performing an investigation as: “Physician determined patient had a pocket infection and made the decision to explant and device. No investigation needed.”\nii. (b)(4), reported on October 28, 2022, that subsequently became Complaint-00039, documents the “Initiate Investigation Process” option was selected but no investigation was performed and the “Review for Closure” section of the complaint records lists “no investigation needed.”\nWe reviewed your firm’s responses and conclude that they are not adequate. In the response, your firm states that CAPA 00015 was opened to capture all corrective and preventive work performed in relation to this observation. As part of CAPA 00015, your firm promised to (b)(4). Your firm also promised to (b)(4). However, the response does not address performing a retrospective review of all issues and nonconforming product reports to determine if other complaints exist and if investigations need to be performed. Several of the items promised by your firm continue to be in-progress (including but not limited to (b)(4).\n2. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR 820.90(a).\nSpecifically, your Nonconformance Material Procedure, #1707-002, does not include a provision for the determination of the need for an investigation. For example, the following two nonconformances did not include a documented investigation or evaluation:\na. (b)(4) was created on June 27, 2024, for IMD batteries that were sent to your contract manufacturer for use in production were returned due to nonconformances (bent prongs). The disposition of the batteries was recorded as being scrapped. However, there was no investigation conducted into the cause of the bent probes and the nonconformance record does not include a rationale for not investigating.\nb. (b)(4) was created on June 7, 2023, for the EXD-001 Battery Packaging Label (p\u002Fn (b)(4)) on the EXD-001 Battery, 10 Packs (p\u002Fn (b)(4)) listing an incorrect expiration date and battery lot code in finished goods inventory. Your firm reworked the nonconforming product. However, there was no investigation conducted into the cause of the incorrect labeling and the nonconformance record does not include a rationale for not investigating.\nWe reviewed your firm’s responses and conclude that they are not adequate. Your response promises to (b)(4) as well as plans to (b)(4). All activities are captured in CAPA 00017 and all work is promised by (b)(4). However, your response fails to address if a retrospective review of NCMRs will be conducted. Several of these promised actions (including CAPA 00017) remain in-progress with a tentative CAPA Effectiveness Verification planned due date of (b)(4).\n3. Failure to adequately establish and maintain procedures for validating the device design to include adequate risk analysis, as required by 21 CFR 820.30(g). Specifically, section 6.14 of your Risk Management Procedure, #1701-011, covers the information collection, information review, and actions related to the use of the Corrective and Preventive Action System and the Complaint System to monitor the device in the clinical and post-production phase to determine if reassessment of risks and\u002For assessment of new risks is necessary. Your firm failed to reassess the risk when estimated risks from a hazard differed from the actual risk observed in post-market CAPA and complaint data. For example:\na. Your firm has received three complaints of infection with the IMD portion of the Guardian System out of a total of (b)(4) IMDs implanted as of February 25, 2025. The observed rate of infection is (b)(4)%. In your device risk file, Guardian System Risk Assessment – P18, #0201-0200-001#P18, Rev B, dated November 13, 2023, the rate of infection was estimated to be (b)(4)%. The risk was not reassessed.\nb. Your firm has received 24 complaints of battery failure due to electrical short before the device reached its expected service life of 6 years, causing patients to opt for early explant and\u002For replacement. The observed rate of battery failure is (b)(4)%. In your device risk file, IMD AMSG3-E Hardware FMECA Report – P16, #0212-0201-001#P16, Rev A; dated February 24, 2015, the rate of battery failure was estimated to be (b)(4)%. Further, your firm initiated CAPA-00012 in response to the battery failures. The “Process Impacts” section of this CAPA indicates that no updates to risk management were needed. The risk was not reassessed.\nWe reviewed your firm’s responses and conclude that they are not adequate. In the response, your firm indicates that CAPA 00016 was opened to address any corrective and preventive work taken as result of the observation including to assess the risk associated with infection using current performance data against historical data and to address the need to perform risk reviews on a regularly scheduled basis to keep the risk data current by July 1, 2025. However, your firm did not indicate if you intend to review, and update as necessary, the risk file utilizing post-market data for items other than risk of infection. Several of the items promised by your firm continue to be in-progress, including but not limited to (b)(4) which has a (b)(4) planned due date of (b)(4).\n4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm failed to follow your procedure, Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, when taking corrective and preventive actions. Two examples of lack of CAPA procedure implementation are as follows:\na. Your firm failed to follow your CAPA process for a corrective action taken as a result of a consumer complaint which led to a revision made to manufacturing procedure Process Specification, PROG-004 Final Shipping Manufacturing, #0217-1200-020#P18, Rev F, dated November 19, 2024. These actions were taken outside of the CAPA system and lack a documented CAPA investigation as well as verification of implementation and effectiveness.\nb. Your firm failed to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). Specifically, section 5.9 of the Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, describes your firm’s process for establishing verification of effectiveness plans with predetermined criteria that verify if corrective and\u002For preventive actions were effective. Additionally, section 5.10 of the Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, describes the process for conducting the verification of effectiveness (VOE) phase to demonstrate effectiveness.\nReview of five CAPAs closed between January 2022 and the time of the current inspection disclosed that four CAPAs (CAPA-00007, CAPA-00008, CAPA-00010, and CAPA-00014) lacked evidence that your firm verified or validated that the action taken was effective.\nFor example, CAPA-00007, was opened as a result of the previous inspection on March 15, 2022, related to a complaint involving EXD batteries having expired shelf life. Your firm implemented several corrective actions to correct the issue which were documented utilizing the complaint record (complaint number 00013) instead of through the CAPA system. CAPA-00007 was closed on March 31, 2022, without verifying the effectiveness of the correction and preventive actions taken.\nWe reviewed your firm’s responses and conclude that they are not adequate. In this response, your firm opened CAPA 00016 to document actions taken for this observation. Your firm promises to (b)(4). For the 5 CAPAs lacking VOE plans and reports, your firm asks our Agency if (b)(4) (2021 or earlier). The decision to (b)(4) remains your firm’s decision as long as it is based on a rationale you determine to be appropriate given the 21 CFR 820.100(a)(4) and your own procedural requirement to demonstrate effectiveness of a CAPA action. You are also going to (b)(4). Your response does not address if other CAPAs will be reviewed to determine if (b)(4). Several of the items promised by your firm continue to be in-progress (including but not limited to (b)(4).\n5. Failure to validate with a high degree of assurance and approve according to established procedures, a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). Specifically, your firm’s Process Validation Procedure, #1705-002, Rev E, dated October 23, 2020, and Process Qualification Procedure, #1705-001, Rev F, dated October 23, 2020, were not adequately established in that both procedures fail to address sterilization validation. Your firm’s implantable cardiac monitoring device (IMD) undergoes (b)(4) sterilization. Further, the two procedures fail to document the process of requalification and revalidation (if necessary) of the sterilization cycle.\nFor example, the (b)(4) sterilization process for your firm’s IMD was last performed in June 2022 by a 3rd party in accordance with FDA-recognized standard ANSI\u002FAAMI\u002FISO 11135:2014. Your firm has not reviewed the (b)(4) sterilization process since the 2022 requalification.\nWe reviewed your firm’s responses and conclude that they are not adequate. In the responses, you indicate that CAPA 00019 was opened as a result of the observation and that your firm promises to (b)(4). However, your responses do not address if your firm’s plans to revise your process validation procedures to include sterilization. Additionally, supporting evidence (including CAPA 00019) of these promised actions remain in progress with a CAPA Effectiveness Verification planned due date for CAPA 00019 of (b)(4).\n6. Failure to adequately establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants, as required by 21 CFR 820.50(a). Specifically, your Supplier Management Procedure (#1703-003), has not been fully implemented. For example:\na. Your firm’s Supplier Management Procedure (#1703-003) describes a process for supplier evaluation and acceptance using a supplier evaluation form. The Supplier Evaluation Form for the IMD battery supplier, (dated February 13, 2020), indicated your firm’s contract manufacturer would perform receiving inspections of these batteries and provide (b)(4) to Avertix. Your QA\u002FQC manager stated these (b)(4) were not completed.\nb. Your firm failed to adequately establish and maintain records of acceptable suppliers, contractors, and consultants, as required by 21 CFR 820.50(a)(3). Specifically, section 7.1.12 of Supplier Management Procedure, Rev K, states that “Quality Assurance is responsible for revising the Approved Supplier List with changes made based on acceptance\u002Frejection of potential suppliers\u002Fre-evaluated suppliers\u002Fdeactivated suppliers…” A software supplier used by your firm since 2023 to meet the requirements of the Medical Device Tracking regulation was not listed on your Approved Supplier List (Rev L, dated June 15, 2023).\nWe reviewed your firm’s responses and conclude that they are not adequate. In the responses, your firm promises and provided revisions to your Supplier Management Procedure (Document 1703-003) removing the requirement for (b)(4) for your contract manufacturer and to evidence of a new supplier evaluation for the software supplier utilized for medical device tracking by July 1, 2025. The responses do not indicate if other supplier evaluations will be evaluated and updated, as needed. Further, CAPA 00023 remains in progress with a CAPA Effectiveness Verification planned due date of December 1, 2025.\nMedical Device Reporting (MDR) Violations\nOur inspection also revealed that your firm’s Guardian System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 803 - Medical Device Reporting was promulgated under section 519 of the Act, among other provisions. Significant violations include, but are not limited to, the following:\n1. Failure to report to the FDA the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\nFor example, the information included for Complaint-00066, Issue-00091, and Complaint-00039 reasonably suggests that each patient sustained an injury or illness (i.e., infection) following implantation of your firm’s Guardian System. These infections constituted serious injuries within the meaning of 21 CFR 803.3(w) because they necessitated surgical intervention (i.e., explantation) to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of information that reasonably suggests that the Guardian System may have caused or contributed to a serious injury on February 13, 2024, for Complaint-00066, on November 6, 2023, for Issue-00091, and on October 28, 2022, for Complaint-00039. As such, Complaint-00066, Issue-00091, and Complaint-00039 represent MDR reportable events, as defined in 21 CFR 803.3(o)(2)(i). However, the FDA did not receive an MDR for each referenced event until April 10, 2025, which exceeded the required 30 calendar day reporting timeframe.\nThe adequacy of your firm’s responses cannot be determined at this time. We acknowledge that the FDA received the manufacturer reports, submitted using the electronic equivalent of Form 3500A, for the referenced serious injury events after the 30 calendar day reporting timeframe had elapsed. However, although the response referenced the updated MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, as part of its correction action for the late reporting issue, a copy of the updated MDR procedure was not included.\n2. Failure to report to the FDA the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\nFor example, the information included for Complaints No. 00057, 00065, 00070, 00071, 00072, 00074, 00077, 00079, 00080, 00082, 00083, and 00086, reasonably suggests that your firm’s Guardian System malfunctioned while in use. Specifically, the device prematurely reached its end of service due to early battery depletion, meaning that it failed to meet its performance specifications or otherwise perform as intended under 21 CFR 803.3(k). Your firm initiated recall Z-1140-2025 for the referenced malfunction. A malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the Act as a result of the malfunction of the device or other similar devices. See Medical Devices; Medical Device User Facility and Manufacturer Reporting, Certification and Registration, 60 Fed. Reg. 63585 (Dec. 11, 1995) (referring to section 519(f), which has since been redesignated as section 519(g)). As such, the referenced complaints represent MDR reportable events, as defined under 21 CFR 803.3(o)(2)(ii).\nYour firm became aware of information on the following dates that reasonably suggests that the Guardian System had malfunctioned and this device or a similar device your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur: October 10, 2023, for Complaint No. 00057; February 26, 2024, for 00065; May 28, 2024, for 00070; May 14, 2024, for 00071; May 5, 2024, for 00072; May 14, 2024, for 00074; July 17, 2024, for 00077; August 29, 2024, for 00079; August 21, 2024, for 00080; November 19, 2024, for 0008; November 19, 2024, for 00083; and December 3, 2024, for 00086. Your firm submitted a report for each event using the MedWatch Online Voluntary Reporting Form. Specifically, MW5149541 (Complaint No. 00057), MW5153561 (Complaint No. 00065), MW5159171 (Complaint No. 00070), MW5159172 (Complaint No.00071), MW5159173 (Complaint No. 00072), MW5159805 (Complaint No. 00074), MW5160629 (Complaint No. 00077), MW5160632 (Complaint No. 00079), MW5160633 (Complaint No. 00080), MW5164478 (Complaint No. 00082), MW5164476 (Complaint No. 00083), and MW5164481 (Complaint No. 00086). The submission of reports using the voluntary MedWatch Online Voluntary Reporting Form does not fulfill reporting obligations arising under 21 CFR Part 803. An electronic submission of a mandatory report from a manufacturer must contain the information from the applicable blocks of Form FDA 3500A. All medical device reports must be submitted within the required timeframes. However, the FDA did not receive the corresponding MDRs until April 14, 2025, which exceeded the required 30 calendar day reporting timeframe.\nThe adequacy of your firm’s responses cannot be determined at this time. We acknowledge that the FDA received the manufacturer reports, submitted using the electronic equivalent of Form 3500A, for the referenced malfunction events based on your firm’s retrospective review on April 14, 2025, after the 30 calendar day reporting timeframe had elapsed.\nHowever, although the response referenced the updated MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, as part of its correction action for the late reporting issue, a copy of the updated MDR procedure was not included.\nIn addition, the inspection revealed that your firm failed to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, your firm presented the document titled “Medical Device Vigilance Procedures,” Document No. 1716-005, Rev. F, dated June 25, 2024, as its MDR procedure. Upon review, we conclude that the MDR procedure does not develop, maintain, and implement written MDR procedures for internal systems that provide for timely transmission of complete medical device reports to FDA, as required by 21 CFR 803.17(a)(3). Specifically, the procedure 1716-005, Rev. F does not include instructions for how your firm will comply with the 21 CFR 803.12(a) requirement to submit reports to FDA in an electronic format that FDA can process, review, and archive. As a manufacturer, you must submit reports of individual adverse events to FDA in an electronic format in accordance with 21 CFR 803.12(a) and 803.20, unless granted an exemption under 21 CFR 803.19.\nThe adequacy of your firm’s responses cannot be determined at this time. While your response included a copy of the updated Complaint Procedure, Document No.1716-002, and staff training records, it referenced an update to the MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, without including a copy. Without the referenced document, we cannot fully assess the adequacy of the response.\nCorrections and Removals Violation\nOur inspection also revealed that your firm’s Guardian System Model AMSG3‐E IMD implant devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals was promulgated under section 519 of the Act, among other provisions. Violations include, but are not limited to, the following:\nFailure to submit to the FDA within 10 working days of initiating a correction or removal a report required by 21 CFR 806.10.\nSpecifically, on September 18, 2023, Avertix Medical, Inc., delivered a letter to physicians who have patients implanted with a Model AMSG3‐E IMD manufactured during the period when a contamination issue was occurring on the battery production line. This issue led to premature battery depletion in the Guardian System implants, which can result in failure to monitor and earlier‐than‐expected implant replacement surgery. The letter recommends reducing the interval of regular follow-up visits and reinforcing the patient training. FDA determined that shorter device implant life leading to sooner than expected replacement surgery may present a risk to health. This action constitutes a medical device correction or removal initiated to reduce a risk to health posed by the device or remedy a violation of the Act caused by the device which may present a risk to health under 21 CFR 806.10(a). Accordingly, you were required to submit a Report of Correction or Removal to FDA within 10 working days of initiation, under 21 CFR 806.10(b). You submitted a Medical Device Report of Correction or Removal to FDA for this action on December 11, 2024.\nWe reviewed your firm’s responses and conclude that they are not adequate. The responses do not contain evidence that your firm’s procedures will result in compliance with the medical device correction and removal reporting requirements in 21 CFR 806. CAPA 00020 states that management failed to recognize that it needed to submit a Report of Correction or Removal within 10 working days of initiation. Your corrective action was retraining personnel in two procedures, Complaint Procedure (1716-002) and Vigilance Procedure (1716-005). You stated that your Quality Management System (QMS) procedure specifies that recalls or corrections must be reported within 10 days. However, your responses did not include a new revision of 1716-005 nor procedure 1716-004, PRODUCT RECALLS, CORRECTIONS AND REMOVALS. Procedure 1716-004 Rev F, collected in the inspection, notes that the Recall Coordinator is responsible for communicating with regulatory agencies within defined reporting times as per the Vigilance procedure. The procedure titled MEDICAL DEVICE VIGILANCE PROCEDURES, 1716-005 Rev F, collected during the inspection, does not describe Reports of Corrections or Removals, required by 21 CFR 806. Therefore, training personnel on 1716-005 will not help personnel know the timeframe for reporting a Medical Device Correction or Removal to FDA.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 711080” when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan, Compliance Officer at sean.moynihan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Avertix Medical, Inc.","avertix-medical-inc-711080-09032025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Favertix-medical-inc-711080-09032025","2026-10-26T08:07:59.649711+00:00","2026-03-17","711080","Timothy P. Moran","2026-08-19T04:50:38.23+00:00","2025-09-03",{"id":94,"raw":95,"subject":100,"body_html":101,"body_text":102,"firm_name":103,"letter_id":104,"created_at":66,"fei_number":19,"letter_url":105,"updated_at":106,"action_type":22,"case_status":23,"posted_date":107,"marcs_cms_no":108,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":109,"body_fetched_at":110,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":111,"medical_device_id":19,"response_letter_date":19},63,[96,97,98,11,99,13,13,13],"\u003Ctime datetime=\"2026-06-30T04:00:00Z\">06\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-20T04:00:00Z\">05\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbmc-medical-co-ltd-725759-05202026\">BMC Medical Co., Ltd.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jian Xu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BMC Medical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 16 Lize Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Room 10, 17F Building 4, Huiya Plaza\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fengtai Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Beijing Shi\u003C\u002Fspan>, \u003Cspan>100073\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 725759\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 20, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Xu:\u003C\u002Fp>\u003Cp>During an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Your firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B Medical, Inc. established that you are the design change authority and 510(k) owner of the device. For example, FDA has reviewed your firm’s nP3_Product System Verification Report_G3-2.11.01 and Design change evaluation report, Project code: nP3 for the Luna G3 APAP, Model LG3600, approved on March 12, 2025, which revealed that the firmware\u002Fsoftware was updated with additional recognition features, i.e., (1) Flow Limitation, (2) Respiratory Effort-Related Arousals (RERA), and (3) Periodic breathing, to distinguish between central hypopnea and obstructive hypopnea events.\u003C\u002Fp>\u003Cp>Furthermore, the sound abatement system of the cleared Luna APAP devices was modified to ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ or ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ and a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> was added to the cleared Luna APAP device to match the sound reduction as a result of the material change. Additionally, the Printed Circuit Board Assembly (PCBA) includes a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> chip compatible with the new algorithm and new data structure master control software. These design modifications to the cleared Luna APAP appear to have given rise to a new model branded as G3X APAP. These changes could significantly affect safety or effectiveness because they are significant changes in the design and materials of these devices. The firmware update introduced new detection algorithms capable of distinguishing between central and obstructive hypopnea events, which affects the accuracy of event classification and the data available to clinicians for evaluating therapy effectiveness and informing future therapy adjustments. The removal of \u003Cstrong>(b)(4)\u003C\u002Fstrong> represents a material change to the gas pathway that raises biocompatibility concerns, and when combined with the addition of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong>, these changes could affect the overall pressure and flow profile of the device, thereby impacting therapy delivery. The addition of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> PCBA chip and updated master control software introduces potential implications for electrical safety and overall device performance. Collectively, these changes represent significant modifications in device design, materials, and software that could significantly affect the safety and effectiveness of the device.\u003C\u002Fp>\u003Cp>FDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” Thus, the G3X APAP is misbranded under 502(o) because of your failure to submit the required premarket notification for the modifications. FDA requests that your firm cease any activities that result in the misbranding or adulteration of your devices.\u003C\u002Fp>\u003Cp>For further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the G3 X APAP devices.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Correction and Removals Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that your firm’s Luna G3 APAP devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\u003C\u002Fp>\u003Cp>Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Luna G3 APAP devices with firmware G3-2.00.76 could cause the Luna G3 APAP device to unexpectedly shut down during use, which causes loss of therapy for patients with obstructive sleep apnea. You communicated with 3B (React Health) in \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The action of updating the firmware to G3-2.00.77 is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA.\u003C\u002Fp>\u003Cp>Your firm has not submitted a Report of Correction or Removal to FDA for the firmware update to G3-2.00.77 as of May 19, 2026.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The inspection of 3B Medical on December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, should any corrective actions you propose or implement relate to device current good manufacturing practice (CGMP) requirements, they must be made pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725759” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara A. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>\u003Cstrong>(b)(4), (b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJian Xu\n\nRecipient Title\n\nPresident\n\nBMC Medical Co., Ltd.\n\nNo. 16 Lize Road\n\nRoom 10, 17F Building 4, Huiya Plaza\n\nFengtai Qu\n\nBeijing Shi, 100073\n\nChina\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 725759\nMay 20, 2026\nDear Mr. Xu:\nDuring an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nUnapproved Device Violations\nOur inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nYour firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B Medical, Inc. established that you are the design change authority and 510(k) owner of the device. For example, FDA has reviewed your firm’s nP3_Product System Verification Report_G3-2.11.01 and Design change evaluation report, Project code: nP3 for the Luna G3 APAP, Model LG3600, approved on March 12, 2025, which revealed that the firmware\u002Fsoftware was updated with additional recognition features, i.e., (1) Flow Limitation, (2) Respiratory Effort-Related Arousals (RERA), and (3) Periodic breathing, to distinguish between central hypopnea and obstructive hypopnea events.\nFurthermore, the sound abatement system of the cleared Luna APAP devices was modified to ‘(b)(4)’ or ‘(b)(4)’ and a new (b)(4) was added to the cleared Luna APAP device to match the sound reduction as a result of the material change. Additionally, the Printed Circuit Board Assembly (PCBA) includes a new (b)(4) chip compatible with the new algorithm and new data structure master control software. These design modifications to the cleared Luna APAP appear to have given rise to a new model branded as G3X APAP. These changes could significantly affect safety or effectiveness because they are significant changes in the design and materials of these devices. The firmware update introduced new detection algorithms capable of distinguishing between central and obstructive hypopnea events, which affects the accuracy of event classification and the data available to clinicians for evaluating therapy effectiveness and informing future therapy adjustments. The removal of (b)(4) represents a material change to the gas pathway that raises biocompatibility concerns, and when combined with the addition of a new (b)(4), these changes could affect the overall pressure and flow profile of the device, thereby impacting therapy delivery. The addition of a new (b)(4) PCBA chip and updated master control software introduces potential implications for electrical safety and overall device performance. Collectively, these changes represent significant modifications in device design, materials, and software that could significantly affect the safety and effectiveness of the device.\nFDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” Thus, the G3X APAP is misbranded under 502(o) because of your failure to submit the required premarket notification for the modifications. FDA requests that your firm cease any activities that result in the misbranding or adulteration of your devices.\nFor further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the G3 X APAP devices.\nCorrection and Removals Violations\nOur inspection also revealed that your firm’s Luna G3 APAP devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\nSignificant violations include, but are not limited to, the following:\n1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Luna G3 APAP devices with firmware G3-2.00.76 could cause the Luna G3 APAP device to unexpectedly shut down during use, which causes loss of therapy for patients with obstructive sleep apnea. You communicated with 3B (React Health) in (b)(4) to (b)(4). The action of updating the firmware to G3-2.00.77 is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA.\nYour firm has not submitted a Report of Correction or Removal to FDA for the firmware update to G3-2.00.77 as of May 19, 2026.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The inspection of 3B Medical on December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, should any corrective actions you propose or implement relate to device current good manufacturing practice (CGMP) requirements, they must be made pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725759” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara A. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\n(b)(4), (b)(6)","BMC Medical Co., Ltd.","bmc-medical-co-ltd-725759-05202026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbmc-medical-co-ltd-725759-05202026","2026-10-26T08:08:06.951272+00:00","2026-06-30","725759","Jian Xu","2026-08-19T04:32:13.877+00:00","2026-05-20",{"id":113,"raw":114,"subject":100,"body_html":117,"body_text":118,"firm_name":119,"letter_id":120,"created_at":18,"fei_number":19,"letter_url":121,"updated_at":122,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":123,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":124,"body_fetched_at":125,"delivery_method":126,"recipient_title":19,"reference_number":19,"action_taken_date":127,"medical_device_id":19,"response_letter_date":19},954,[8,115,116,11,100,13,13,13],"\u003Ctime datetime=\"2025-04-04T04:00:00Z\">04\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ficu-medical-702535-04042025\">ICU Medical\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Vivek Jain\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ICU Medical\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>951 Calle Amanecer\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Clemente\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92673\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS 702535\u003C\u002Fp>\u003Cp>April 04, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Jain:\u003C\u002Fp>\u003Cp>During an inspection of Smiths Medical ASD (acquired by your firm ICU Medical in January 2022) FEI: 3012307300 located at 6000 Nathan Lane N., Minneapolis, Minnesota on July 23, 2024, through August 9, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products is a device because it is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Our inspection revealed that the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\u003Cbr>http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>You currently have clearance, dated August 29, 2011, for a version of the Medfusion® Model 4000 Syringe Infusion Pump which was cleared under K111386 as a Class II device under 21 CFR 880.5725. You also currently have clearance, dated February 1, 2013, for a version of the CADD® Solis VIP Ambulatory Infusion Pump which was cleared under K111275 as a Class II device under 21 CFR 880.5725. However, your firm has failed to submit a premarket notification submission to FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices, as required by 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>In particular, since their last respective clearances, you made multiple changes to the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices, including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the Medfusion® Model 4000 Syringe Infusion Pump as well as \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes for both the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Specifically, these modifications included \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes to address \u003Cstrong>(b)(4)\u003C\u002Fstrong> identified via adverse event reports and \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Such modifications can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality, etc., and affect the device’s risk profile for risks related to under- or over-infusion, delay in therapy, incomplete therapy, or false alarms leading to adverse health effects for patients such as overdose, volume overload, or cardiorespiratory compromise. Your documentation collected during the recent inspection describing the 510(k) risk-benefit analysis for the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump indicates that these changes were implemented after the most recent clearances of the devices as noted above. Further, you have disseminated updated software \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which includes the changes described above, in response to a Class I recall intended to remediate the cause(s) of the recall impacting delivery of fluids, false alarms, therapy interruption, etc. However, you have not yet submitted 510(k)s as required by 21 CFR 807.81(a)(3)(i). Adding a statement to your labeling that the device software has not undergone FDA review is not sufficient.\u003C\u002Fp>\u003Cp>Furthermore, in the regulatory change impact assessment for the Medfusion® Model 4000 Syringe Infusion Pump software update dated April 28, 2023, you identified that a risk-based assessment of the changed device identified new risks or significantly modified risks. Further, you identified that the change either creates or necessitates a new risk control measure or modification of an existing risk control measure for a hazardous situation that could result in significant harm. The changes that you made to the risk control measures in an effort to mitigate the hazards that were the basis for a Class I recall were not submitted to FDA in a required 510(k) even though your own procedure indicates that submission of a 510(k) would be required in this situation. However, you only documented to the file that you had made the change and did not submit the required 510(k).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 702535 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nVivek Jain\n\nRecipient Title\n\nCEO\n\nICU Medical\n\n951 Calle Amanecer\n\nSan Clemente, CA 92673\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS 702535\nApril 04, 2025\nDear Mr. Jain:\nDuring an inspection of Smiths Medical ASD (acquired by your firm ICU Medical in January 2022) FEI: 3012307300 located at 6000 Nathan Lane N., Minneapolis, Minnesota on July 23, 2024, through August 9, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products is a device because it is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nOur inspection revealed that the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nYou currently have clearance, dated August 29, 2011, for a version of the Medfusion® Model 4000 Syringe Infusion Pump which was cleared under K111386 as a Class II device under 21 CFR 880.5725. You also currently have clearance, dated February 1, 2013, for a version of the CADD® Solis VIP Ambulatory Infusion Pump which was cleared under K111275 as a Class II device under 21 CFR 880.5725. However, your firm has failed to submit a premarket notification submission to FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices, as required by 21 CFR 807.81(a)(3)(i).\nIn particular, since their last respective clearances, you made multiple changes to the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices, including the (b)(4) for the Medfusion® Model 4000 Syringe Infusion Pump as well as (b)(4) changes for both the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Specifically, these modifications included (b)(4) changes to address (b)(4) identified via adverse event reports and (b)(4) changes to (b)(4) and (b)(4). Such modifications can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality, etc., and affect the device’s risk profile for risks related to under- or over-infusion, delay in therapy, incomplete therapy, or false alarms leading to adverse health effects for patients such as overdose, volume overload, or cardiorespiratory compromise. Your documentation collected during the recent inspection describing the 510(k) risk-benefit analysis for the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump indicates that these changes were implemented after the most recent clearances of the devices as noted above. Further, you have disseminated updated software (b)(4), which includes the changes described above, in response to a Class I recall intended to remediate the cause(s) of the recall impacting delivery of fluids, false alarms, therapy interruption, etc. However, you have not yet submitted 510(k)s as required by 21 CFR 807.81(a)(3)(i). Adding a statement to your labeling that the device software has not undergone FDA review is not sufficient.\nFurthermore, in the regulatory change impact assessment for the Medfusion® Model 4000 Syringe Infusion Pump software update dated April 28, 2023, you identified that a risk-based assessment of the changed device identified new risks or significantly modified risks. Further, you identified that the change either creates or necessitates a new risk control measure or modification of an existing risk control measure for a hazardous situation that could result in significant harm. The changes that you made to the risk control measures in an effort to mitigate the hazards that were the basis for a Class I recall were not submitted to FDA in a required 510(k) even though your own procedure indicates that submission of a 510(k) would be required in this situation. However, you only documented to the file that you had made the change and did not submit the required 510(k).\nYour firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 702535 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","ICU Medical","icu-medical-702535-04042025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ficu-medical-702535-04042025","2026-10-26T08:08:57.251119+00:00","702535","Vivek Jain","2026-08-19T16:52:11.735+00:00","VIA UNITED PARCEL SERVICE","2025-04-04",{"id":129,"raw":130,"subject":134,"body_html":136,"body_text":137,"firm_name":138,"letter_id":139,"created_at":140,"fei_number":19,"letter_url":141,"updated_at":142,"action_type":22,"case_status":143,"posted_date":144,"marcs_cms_no":145,"product_type":26,"closeout_date":146,"issuing_office":11,"recipient_name":147,"body_fetched_at":148,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":149,"medical_device_id":19,"response_letter_date":19},2483,[131,132,133,11,134,13,135,13],"\u003Ctime datetime=\"2022-08-30T13:20:00Z\">08\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-03T04:00:00Z\">08\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022\">USA Medical LLC\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-02062023\">\u003Ctime datetime=\"2023-02-09T05:00:00Z\">02\u002F09\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Damon H. Roberts\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>USA Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1220 Texan Trail, Suite 205\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grapevine\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76051-4164\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:damon@USAMedicalllc.com\"> damon@USAMedicalllc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 631500\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 3, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Roberts:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID-19 Ag Rapid Test\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>Your products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm distributed at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> kit has defined storage requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-%20fdas-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>This response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\u003C\u002Fp>\n\n\u003Cp>If you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D. Director\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The “\u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test” distributed by your firm appears to be the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Rapid Test for use outside of these specified settings.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential%E2%80%90actions\u002Fproclamation%E2%80%90declaring%E2%80%90national%E2%80%90%20emergency-concerning%E2%80%90novel%E2%80%90coronavirus%E2%80%90disease%E2%80%90covid%E2%80%9019%E2%80%90outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDamon H. Roberts\n\nRecipient Title\n\nPresident\u002FOwner\n\nUSA Medical LLC\n\n1220 Texan Trail, Suite 205\n\nGrapevine, TX 76051-4164\n\nUnited States\n\ndamon@USAMedicalllc.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 631500\n\nAugust 3, 2022\n\nDear Mr. Roberts:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, (b)(4) COVID-19 Ag Rapid Test1 (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-192 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nOur inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nYour products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.3 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.4 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”5 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nOur inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\n\n1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\n\nSpecifically, your firm distributed at least (b)(4) SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\n\n2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\n\nSpecifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\n\n3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\n\nSpecifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than (b)(4) test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\n\n4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\n\nSpecifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\n\n5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\n\nSpecifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\n\n6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\n\nSpecifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\n\n7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\n\nSpecifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The (b)(4) kit has defined storage requirements.\n\n8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\n\nSpecifically, (b)(4) boxes containing (b)(4) Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\n\n9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\n\nSpecifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\n\nSpecifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\n\nSpecifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\n\n12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\n\nSpecifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\n\nOur inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nSpecifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\n\nYour firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nThis response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\n\nIf you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D. Director\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3\n\nOffice of Regulatory Affairs\n\n___________________________\n\n1 The “(b)(4) COVID‐19 Ag Rapid Test” distributed by your firm appears to be the (b)(4) COVID‐19 Ag Rapid Test manufactured by (b)(4). On (b)(4), FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of (b)(4) COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the (b)(4) COVID‐19 Rapid Test for use outside of these specified settings.\n\n2 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n4 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F.\n\n5 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","USA Medical LLC","usa-medical-llc-631500-08032022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022","2026-10-26T08:10:18.402099+00:00","Closed Out","2022-08-30","631500","2023-02-09","Damon H. Roberts","2026-08-20T01:37:57.067+00:00","2022-08-03",7,{"510k":152,"classification":153,"enforcement":154,"event":155,"event_backfill":156,"pma":157,"warning_letter":158},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]